Preclinical News and Research

RSS

Amazon jungle plant compound blocks tissue destruction

Scientists at Case Western Reserve University's School of Medicine have published in the Journal of Inflammation a remarkable discovery with a natural product derived from the Amazon rainforest.

24 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Potent inhibitor of Kinesin CENP-E demonstrates tumor cell inhibition

A first-in-class, targeted investigational therapy specifically designed to inhibit a single protein that functions only during cell division shows potent activity in a broad range of cancer cell lines, say researchers from GlaxoSmithKline.

24 Oct 2007

Combo therapy flavopiridol and cisplatin shows promise for recurrent ovarian cancer resistant to platinum therapy

Mayo Clinic has reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy.

24 Oct 2007

Orexigen presents findings on obesity drug candidates

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.

24 Oct 2007

Experimental cancer pharmaceuticals under trial

A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro: Abstract A 111.

24 Oct 2007

Severely restricting calories leads to a longer life

New research now has shown for the first time that such a diet also can maintain physical fitness into advanced age, slowing the seemingly inevitable progression to physical disability and loss of independence.

22 Oct 2007

More educated people who develop dementia lose their memory faster

People with more years of education lose their memory faster than those with less education in the years prior to a diagnosis of dementia, according to a study by researchers at Albert Einstein College of Medicine of Yeshiva University, published in the October 23rd issue of the medical journal Neurology.

22 Oct 2007

GenVec receives extra funding for adenovector-based HIV vaccines program

GenVec, Inc. has announced that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has executed its sixth option period (year seven) under its multi-year collaboration with GenVec to develop and manufacture novel adenovector-based HIV vaccines.

22 Oct 2007

Abbott creates one molecule with two antibody functions

Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.

19 Oct 2007

Existing drugs may be useful in treating brain tumors

Scientists have shown how developing brain tumors can turn an encounter with a signaling molecule from a fatal experience for the tumor cells into a cue for their own growth and multiplication.

17 Oct 2007

AngioGenex files patent on first small molecule Id-inhibitors

AngioGenex Inc. has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins.

17 Oct 2007

Researchers specifically manipulate tumor angiogenesis gene

Angiogenesis is a common process that is essential for tumor growth beyond 2 mm. Although numerous growth factors are involved, vascular endothelial growth factor (VEGF), particularly VEGF-A, has been shown to play an important role in tumor angiogenesis.

16 Oct 2007

Brookhaven's D-peptides halt HIV entry into cells

Based in part on protein structures determined at the National Synchrotron Light Source (NSLS) at the U.S. Department of Energy's Brookhaven National Laboratory, scientists at the University of Utah have developed new peptides that appear to be significantly more effective at blocking HIV's entry into cells than other drugs in their class.

10 Oct 2007

New peptides inhibit HIV's entry into cells

9 Oct 2007

Early stage drug shows promise against cancer cells from young patients

A new drug has shown promising pre-clinical activity against cells from several types of children's cancers, scientists reveal at the National Cancer Research Institute Conference in Birmingham today (Tuesday).

2 Oct 2007

Tree bark compound gambogic amide stimulates growth, survival of brain cells

Researchers have identified a compound in tree bark that mimics the chemical reactions of a naturally occurring molecule in the brain responsible for stimulating neuronal cell signaling.

2 Oct 2007

Ostructive sleep apnea and continuous positive airway pressure

Researchers in Brazil have found that treating patients who suffer from obstructive sleep apnea (OSA) with continuous positive airway pressure (CPAP) dramatically reduces early indications of atherosclerosis in just months, linking OSA directly to the hardening or narrowing of the arteries.

29 Sep 2007

Hydrogen sulfide based drug shows promise in reducing heart-attack damage

Producing a state of "hibernation on demand" in mice by administering an experimental drug from Ikaria (an injectable formulation of the biological gas hydrogen sulfide) showed promise in a study designed to reduce damage from heart attacks.

26 Sep 2007